KR100333148B1 - 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체 - Google Patents
당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체 Download PDFInfo
- Publication number
- KR100333148B1 KR100333148B1 KR1019940703738A KR19940703738A KR100333148B1 KR 100333148 B1 KR100333148 B1 KR 100333148B1 KR 1019940703738 A KR1019940703738 A KR 1019940703738A KR 19940703738 A KR19940703738 A KR 19940703738A KR 100333148 B1 KR100333148 B1 KR 100333148B1
- Authority
- KR
- South Korea
- Prior art keywords
- soluble
- mice
- chains
- cell receptor
- cells
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract description 12
- 229940124597 therapeutic agent Drugs 0.000 title abstract description 10
- 108091008874 T cell receptors Proteins 0.000 title abstract description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 8
- 206010012601 diabetes mellitus Diseases 0.000 title description 7
- 230000003449 preventive effect Effects 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 20
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims description 5
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 22
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 13
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 35
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 230000001506 immunosuppresive effect Effects 0.000 description 15
- 101150033948 tsf gene Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 206010062016 Immunosuppression Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101100293284 Mus musculus Nacad gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP93-031501 | 1993-02-22 | ||
JP3150193 | 1993-02-22 | ||
JP93-179062 | 1993-07-20 | ||
JP17906293A JP3875730B2 (ja) | 1993-02-22 | 1993-07-20 | 自己免疫疾患の予防治療剤 |
PCT/IB1994/000029 WO1994019470A1 (en) | 1993-02-22 | 1994-02-22 | Soluble t-cell receptor alpha chain and derivatives used as prophylactic and therapeutic agents for autoimmune diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950701387A KR950701387A (ko) | 1995-03-23 |
KR100333148B1 true KR100333148B1 (ko) | 2002-12-02 |
Family
ID=26369980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940703738A KR100333148B1 (ko) | 1993-02-22 | 1994-02-22 | 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5648332A (ja) |
EP (1) | EP0667908B1 (ja) |
JP (1) | JP3875730B2 (ja) |
KR (1) | KR100333148B1 (ja) |
AT (1) | ATE269409T1 (ja) |
AU (1) | AU686134B2 (ja) |
CA (1) | CA2134083C (ja) |
DE (1) | DE69433844T2 (ja) |
DK (1) | DK0667908T3 (ja) |
ES (1) | ES2224105T3 (ja) |
PT (1) | PT667908E (ja) |
WO (1) | WO1994019470A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7811800B2 (en) | 2005-04-11 | 2010-10-12 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
US8188224B2 (en) | 2005-04-11 | 2012-05-29 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
US11982670B2 (en) | 2023-02-01 | 2024-05-14 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08149981A (ja) * | 1993-12-13 | 1996-06-11 | La Jolla Inst For Allergy & Immunology | T細胞α鎖による抗原特異的免疫制御の方法 |
WO1997043411A1 (fr) * | 1996-05-10 | 1997-11-20 | Kirin Beer Kabushiki Kaisha | Peptides a regions constantes de chaine alpha de recepteur des cellules t, leurs procedes de production et leur utilisation |
US6162609A (en) * | 1997-12-31 | 2000-12-19 | The Brigham And Women's Hospital, Inc. | Diagnostic and therapeutic methods based upon Vα24JαQT cells |
EP2158923B1 (en) | 1998-08-06 | 2013-02-27 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
US9078843B2 (en) | 2005-09-22 | 2015-07-14 | Irun R. Cohen | Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL86278A (en) * | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
US6416971B1 (en) * | 1990-05-15 | 2002-07-09 | E.R. Squibb & Sons, Inc. | Soluble single chain T cell receptors |
ES2271940T3 (es) * | 1991-02-08 | 2007-04-16 | Aventis Pharma S.A. | Secuencias nucleotidicas que codifican regiones variables de cadenas alfa de los receptores de linfocitos humanos asi como sus aplicaciones. |
WO1992016234A1 (en) * | 1991-03-22 | 1992-10-01 | The Trustees Of The University Of Pennsylvania | Method of modulating mammalian t-cell response |
-
1993
- 1993-07-20 JP JP17906293A patent/JP3875730B2/ja not_active Expired - Fee Related
-
1994
- 1994-02-22 EP EP94906987A patent/EP0667908B1/en not_active Expired - Lifetime
- 1994-02-22 DE DE69433844T patent/DE69433844T2/de not_active Expired - Lifetime
- 1994-02-22 AT AT94906987T patent/ATE269409T1/de active
- 1994-02-22 KR KR1019940703738A patent/KR100333148B1/ko not_active IP Right Cessation
- 1994-02-22 DK DK94906987T patent/DK0667908T3/da active
- 1994-02-22 WO PCT/IB1994/000029 patent/WO1994019470A1/en active IP Right Grant
- 1994-02-22 ES ES94906987T patent/ES2224105T3/es not_active Expired - Lifetime
- 1994-02-22 US US08/318,881 patent/US5648332A/en not_active Expired - Lifetime
- 1994-02-22 CA CA002134083A patent/CA2134083C/en not_active Expired - Fee Related
- 1994-02-22 AU AU60428/94A patent/AU686134B2/en not_active Ceased
- 1994-02-22 PT PT94906987T patent/PT667908E/pt unknown
Non-Patent Citations (1)
Title |
---|
Proc. Natl. Acad. Sci. USA Vol.87:5248-5252 (1990.7. ) * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9670467B2 (en) | 2005-04-11 | 2017-06-06 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US8034594B2 (en) | 2005-04-11 | 2011-10-11 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US7811800B2 (en) | 2005-04-11 | 2010-10-12 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US10160958B2 (en) | 2005-04-11 | 2018-12-25 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US8178334B2 (en) | 2005-04-11 | 2012-05-15 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US8188224B2 (en) | 2005-04-11 | 2012-05-29 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
US8293228B2 (en) | 2005-04-11 | 2012-10-23 | Savient Pharmaceuticals Inc. | Variant form of urate oxidase and use thereof |
US8465735B2 (en) | 2005-04-11 | 2013-06-18 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US11781119B2 (en) | 2005-04-11 | 2023-10-10 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
US7964381B2 (en) | 2005-04-11 | 2011-06-21 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
US10731139B2 (en) | 2005-04-11 | 2020-08-04 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
US11345899B2 (en) | 2005-04-11 | 2022-05-31 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
US10823727B2 (en) | 2009-06-25 | 2020-11-03 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
US11598767B2 (en) | 2009-06-25 | 2023-03-07 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
US11639927B2 (en) | 2009-06-25 | 2023-05-02 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
US11982670B2 (en) | 2023-02-01 | 2024-05-14 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
Also Published As
Publication number | Publication date |
---|---|
AU6042894A (en) | 1994-09-14 |
KR950701387A (ko) | 1995-03-23 |
PT667908E (pt) | 2004-09-30 |
DE69433844D1 (de) | 2004-07-22 |
WO1994019470A1 (en) | 1994-09-01 |
ATE269409T1 (de) | 2004-07-15 |
ES2224105T3 (es) | 2005-03-01 |
EP0667908A1 (en) | 1995-08-23 |
JPH06298662A (ja) | 1994-10-25 |
DK0667908T3 (da) | 2004-10-11 |
EP0667908B1 (en) | 2004-06-16 |
CA2134083A1 (en) | 1994-09-01 |
AU686134B2 (en) | 1998-02-05 |
DE69433844T2 (de) | 2005-04-21 |
US5648332A (en) | 1997-07-15 |
JP3875730B2 (ja) | 2007-01-31 |
CA2134083C (en) | 2000-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10806771B2 (en) | Compositions and methods for modulating the immune system | |
EP0663836B1 (en) | Treatment of autoimmune and inflammatory disorders | |
US8329637B2 (en) | Method for the treatment of automimmune diseases comprising administering rapamycin and IL-10 | |
CA2182289C (en) | Immuno-stimulatory monoclonal antibodies | |
US20150376278A1 (en) | Use of a cd28 binding pharmaceutical substance for making a pharmaceutical composition with dose-dependent effect | |
KR20040036684A (ko) | 치료용 결합 분자 | |
JPH09509646A (ja) | 多発性硬化症を治療する方法 | |
CA2110055C (en) | T cell receptor peptides as therapeutics for immune-related disease | |
KR100333148B1 (ko) | 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체 | |
JP2607751B2 (ja) | 自己免疫性ブドウ膜網膜炎の治療予防薬 | |
JP2003527400A (ja) | 免疫調節のための方法および組成物 | |
US5643572A (en) | Methods and compositions for the modulation of host immune response to an allergen | |
EP2692733B1 (en) | Nucleic acids encoding soluble forms of CD83 | |
JPH11501283A (ja) | I型インターフェロンに対する中和活性を有する、インターフェロンレセプターに対するモノクローナル抗体を含んでなる医薬組成物 | |
CN114605553B (zh) | 含有Treg细胞的药物组合物以及在自身免疫性疾病中的用途 | |
CN114349857B (zh) | 一种Treg细胞制备方法以及在自身免疫性疾病方面的应用 | |
KR20070035805A (ko) | 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제 | |
Seddon et al. | Deaggregated homologous immunoglobulin‐peptide conjugates induce peptide‐specific T cell nonresponsiveness in vivo | |
Youn | The immunomodulatory effects of metallothionein on mammalian cellular immunity | |
WO2003086457A2 (en) | Method of treating or preventing autoimmune disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110318 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |